Antidiabetic Medication Approved for Heart Failure With Reduced Ejection Fraction
The FDA recently approved the sodium-glucose cotransporter inhibitor, Farxiga (dapagliflozin) oral tablets to diminish the risk of cardiovascular death and hospitalization in adults with heart failure (New York Heart Association class II-IV) with reduced ejection fraction, with and without type 2 diabetes. The approval was based on data from the landmark phase III, randomized, double-blind, placebo-controlled DAPA-HF trial. Read more.

Anticoagulant Administration Improves COVID-19 Outcomes
According to new research findings, providing hospitalized COVID-19 patients with anticoagulants is associated with improved outcomes. Scientists evaluated the correlation between in-hospital anticoagulation administration and mortality among hospitalized patients, possibly providing clinicians with new understanding regarding the best practices for treating and managing patients once they are admitted. Read more.

No Added Risk With ACE Inhibitors and ARBs in COVID-19 Patients
Recently, the publication of several studies exploring the relationship of angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) with COVID-19 presented reassuring clinical data. Although the results do not indicate that continued utilization of ACE inhibitors and ARBs causes harm, there are some contradictory results in secondary analyses regarding possible variances in the effects of the two drug classes. Read more.